ReviewMedical gas research2027
Gasotransmitters in the regulation of connexins in central and peripheral nervous system injuries.
Review in Medical gas research, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gasotransmitters, such as nitric oxide, carbon monoxide, and hydrogen sulfide can freely diffuse across biological membranes, bind to receptors and molecular targets, and modulate multiple intracellular signaling pathways. However, no systematic review exists regarding how gasotransmitters influence central and peripheral nervous system injury by regulating connexins. This review study presents, for the first time, a systematic analysis of the effects of these three gasotransmitters on connexin regulation, with a focus on their potential roles in injuries to the central and peripheral nervous systems. The results of the systematic analysis showed that carbon monoxide can exert both neuroprotective and neurotoxic effects through S-nitrosylation, phosphorylation, and regulation of connexin channels, as well as contribute to neurovascular coupling and ischemic preconditioning. Carbon monoxide primarily modulates connexin activity via the heme oxygenase-1/carbon monoxide/nuclear factor erythroid 2-related factor 2 signaling pathways, demonstrating potential in reducing neuroinflammation and necroptosis. Hydrogen sulfide also affects connexin-related signaling pathways, regulates platelet aggregation and regulatory T cell-mediated immune responses, and supports vascular homeostasis. Importantly, connexins function as molecular hubs integrating gasotransmitter-dependent signals, thereby mediating both secondary injury cascades and neuroregenerative processes. The obtained results indicate that connexins represent promising therapeutic targets, and pharmacological strategies based on gasotransmitters constitute a novel direction in neuroprotection after neural injury. However, the clinical application of these approaches remains limited, and further studies are required to clarify isoform-specific connexin regulation, optimize gasotransmitter delivery systems, and minimize potential systemic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.